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A new disease concept and call for further elucidation 
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Relatively recently, IgG4-related disease (IgG4-RD) was proposed to be an independent 
chronic inflammatory disorder [1]. It has been thought to be a subtype of SS, but recent 
studies have suggested that Mikulicz’s disease is an IgG4-RD and is distinguishable 
from SS [2, 3]. Characteristic features of IgG4-RD include elevated serum IgG4 levels 
and inflammation of various organs. The primary histopathological characteristics of the 
swollen organs consist of extensive infiltration of IgG4-bearing plasma cells, 
retroperitoneal fibrosis and obliterative phlebitis [4]. Although the aetiology and 
pathogenesis of this disorder are still uncertain, inflammation and the consequent 
fibrosis occur because of excessive production of cytokines by type 2 T helper (Th2) 
cells and regulatory T cells [5]. IgG4-RD can comprise various organ manifestations, 
including dacryoadenitis, sialadenitis, autoimmune pancreatitis, kidney dysfunction, 
retroperitoneal fibrosis and lung disorders. IgG4-RD has been linked to an increased 
incidence of some malignancies [2]. Early intervention with glucocorticoids can 
improve the disease, however, patients often relapse when doses of steroids are tapered 
[6].  
In this issue of Rheumatology, Yamamoto et al. [7] identified a total of 79 patients with 
IgG4-RD, known as Mikulicz’s disease, who were diagnosed between April 1997 and 
October 2013 and were followed up for more than 2 years after the initial induction 
treatment. They analysed various clinical factors using the Cox proportional hazards 
model, performed uni- and multivariate analyses of each clinical factor and identified 
predictors of relapse. For the multivariate analysis, they used the backward elimination 
method and extracted factors having high predictive power. Their results showed that 
the existence of organ involvement was a strong risk factor for relapse. They divided the 
patients into groups with and without organ lesions at diagnosis and performed uni- and 
multivariate analyses for each group.  
Yamamoto et al.’s [7] retrospective statistical study assessed the identification of 
relapse predictors in IgG4-RD at the first visit and initial treatment. They identified 
these predictive factors as male sex and younger age at disease onset in patients without 
organ involvement at diagnosis of IgG4-RD and as low levels of serum IgG4 in patients 
with organ dysfunction at diagnosis. Furthermore, complication with autoimmune 
pancreatitis and low steroid dose at initial treatment tended to be associated with 
recurrence. They thus concluded that male sex and younger age at onset in patients 
without organ damage at diagnosis predicted relapse of IgG4-RD [7]. In addition, 
careful follow-up was important for patients with recognized risk factors for relapse. 
These findings will provide useful information for clinicians in developing a treatment 
plan.  
Although applying data obtained from the statistical analysis to daily clinical practice 
would be preferable, predictions based on such resultant factors may not in fact 
correlate with clinical medicine as practised. For example, one of the predictive factors 
was low levels of serum IgG4 in patients with organ dysfunction at diagnosis, despite 
the article’s finding that organ lesions were related to elevated levels of serum IgG4 at 
diagnosis [7]. However, IgG4-RD itself involves elevated serum levels of IgG4 [7]. 
From a pathological point of view, interpreting the levels of serum IgG4 as the authors 
stated is rather difficult, suggesting the clinicopathological heterogeneity of IgG4-RD. 
In addition, the definition of organ involvement in IgG4-RD seems unclear. IgG4-RD 
has unique clinical, serological, radiological and pathological features associated with 
multiorgan involvement, but how do we estimate the degree of involvement of lacrimal 
and salivary glands, autoimmune pancreatitis, kidney and lung disease, retroperitoneal 
fibrosis and so on? It should be kept in mind that from the multivariate analysis of a 
total of 79 patients with IgG4-related dacryoadenitis/sialadenitis, other organ 
involvement was identified as a risk factor for relapse.  
IgG4-RD is a disorder based on Th2 inflammation [2]. The authors interpreted male 
sex and younger age at onset at diagnosis as being predictors of relapse in IgG4-RD [7]. 
With regard to the relationship between Th1/Th2 cytokine balance and sex hormones, 
oestrogen promotes the Th1 response, whereas progesterone stimulates Th2-related 
inflammation. Although the authors stated that symptoms worsened when a woman with 
IgG4-RD became pregnant [7], we often find that symptoms in patients with rheumatic 
diseases tend to be ameliorated during the late phase of pregnancy because of 
up-regulated production of steroids by the placenta. Therefore the situation is too 
complex to state definitely that male sex and younger age at onset are predictive factors 
of relapse in patients with IgG4-RD. Among patients with organ involvement at the first 
visit who relapsed during the follow-up period, the prevalence of positive RF was 
extremely high compared with other groups [7], which suggests a close relationship 
between IgG4-RD and rheumatic diseases. Also, increased knowledge about the 
aetiology and pathology of these disorders may explain the similarities between 
IgG4-RD and various rheumatic diseases and may allow the development of novel 
treatments of these disorders [8]. 
Increasing clinical awareness of IgG4-RD may lead to consultation with 
rheumatologists regarding the various organ dysfunctions involved and the abnormal 
immune responses observed, which resemble those associated with rheumatic diseases. 
IgG4-RD manifests features of a systemic disease, relapses do not always take the same 
form as the clinical disease and disease relapses are common [6]. Additional studies are 
required to compare different strategies to prevent and treat IgG4-RD and maintain 
disease remission. An algorithm to guide treatment decisions for patients with IgG4-RD 
exists [2]; however, no regimen for the disease includes the use of immunosuppressants. 
Glucocorticoid treatment can achieve short-term clinical remission, but about 2030% of 
patients relapse after steroid doses are reduced [9, 10]. Long-term glucocorticoid 
exposure is associated with substantial morbidity. Improved understanding of disease 
pathogenesis may allow for more targeted immunotherapy. With the advent of biologic 
therapies, interest in targeted treatment with specific inflammatory mediators, such as 
cytokines, in patients with IgG4-RD has increased. Early intervention is required for 
improved outcomes in patients with IgG4-RD. Further efforts are needed to develop an 
understanding of IgG4-RD and resolve the problems shown in Table 1.  
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TABLE 1  Problems in IgG4-RD to be solved 
 
Determine the mechanism of serum IgG4 elevation in 
Th2-associated inflammation of IgG4-RD. 
Clarify the autoimmune pathogenic processes in IgG4-RD. Develop tools to analyse 
quality and quantity in organ 
failures. 
Establish screening procedures for underlying malignancies. 
Elucidate disease susceptibility in different races and districts. 
Determine a worldwide consensus for diagnostic criteria. Provide a therapeutic steroid 
regimen to prevent relapses. Pursue novel therapeutic interventions. 
 
IgG4-RD: IgG4-related disease. 
 
